Translational approaches to disease modifying therapy of type 1 diabetes: an innovative approach towards understanding and arresting type 1 diabetes.


Start Date
End Date
IMI2 - Call 1
Grant agreement number

IMI Funding
17 629 999
EFPIA in kind
12 745 192
633 004
Total Cost31 008 195


Type 1 diabetes affects 17 million people globally and there is no cure; instead, patients must inject themselves with insulin daily and continually check their blood sugar levels to control their condition. The goal of the INNODIA project is to advance our understanding of type 1 diabetes and address the lack of tools and technologies that will allow clinicians to predict, evaluate and prevent the onset and progression of type 1 diabetes. For patients, this would mean the ability to predict the rate at which their disease will progress. The knowledge and tools generated by the project will help researchers to optimise the design of clinical trials of treatments for preventing and curing this debilitating disease. The project has set up a patient advisory committee to ensure the work is in line with patients’ needs.

Achievements & News

INNODIA recruits first patients for diabetes study
The INNODIA project has recruited the first patient in a major clinical study of type 1 diabetes. The goal of INNODIA is to improve our understanding of type 1 diabetes and so pave the way for the development of novel treatments to prevent and cure it. ### In the new study, scientists will collect blood samples and data from people just diagnosed with type 1 diabetes and their relatives. They will then follow the evolution of the disease in the study participants. ‘This way we will be able to better understand the relationship between changes in beta cell function, immune profiles, genetic and environmental factors and their role in the onset of the disease,’ says INNODIA coordinator Chantal Mathieu of the University of Leuven in Belgium. Patients were heavily involved in the design of the study. ‘Listening to the patient’s voice and following their advice was crucial in setting up this effort,’ said Olivier Arnaud of JDRF International. Looking to the future, the project will open further study centres in Europe, giving more patients the opportunity to take part. In a video, diabetes patient and INNODIA Patient Advisory Committee member Kyle Rose explains: ‘These [studies] are what are going to allow new therapies, new drugs to be developed so that we can all lead healthier lives as people with diabetes. It can really make a difference.’
(December 2016)

Participants Show participants on map

EFPIA companies
  • Eli Lilly and Company Ltd, Basingstoke, United Kingdom
  • Glaxosmithkline Research And Development LTD, Brentford, Middlesex, United Kingdom
  • Novo Nordisk A/S, Bagsvaerd, Denmark
  • Sanofi-Aventis Deutschland GMBH, Frankfurt / Main, Germany
Universities, research organisations, public bodies, non-profit groups
  • Academisch Ziekenhuis Leiden - Leids Universitair Centrum, Leiden, Netherlands
  • Centre hospitalier de Luxembourg, Luxembourg, Luxembourg
  • Hannoversche Kinderheilanstalt, Hannover, Germany
  • Helmholtz Zentrum Muenchen, Deutsches Forschungszentrum fuer Gesundheit und Umwelt (GmbH), Neuherberg, Germany
  • Institut National De La Sante Et De La Recherche Medicale, Paris, France
  • Katholieke Universiteit Leuven, Leuven, Belgium
  • King's College London, London, United Kingdom
  • Københavns Universitet (University of Copenhagen), Copenhagen, Denmark
  • Medical University of Graz, Graz, Austria
  • Oslo universitetssykehus HF, Oslo, Norway
  • Oulun Yliopisto, Oulu, Finland
  • Region Hovedstaden, Hilleroed, Denmark
  • Slaski Uniwersytet Medyczny w Katowicach, Katowice, Poland
  • Stichting Katholieke Universiteit / Radboud university medical center, Nijmegen, Netherlands
  • Technische Universitat Dresden, Dresden, Germany
  • Universita' Degli Studi Di Siena, Siena, Italy
  • Universita Di Pisa, Pisa, Italy
  • Universitaet Ulm, Ulm, Germany
  • University of Cambridge, Cambridge, United Kingdom
  • University of Helsinki, University of Helsinki, Helsinki, Finland
  • University of Ljubljana, Ljubljana, Slovenia
  • University of Turku, Turku, Finland
  • Università degli Studi 'G.d'Annunzio', Chieti-Pescara, Chieti, Italy
  • Université Libre de Bruxelles, Bruxelles, Belgium
  • Université de Lausanne, Lausanne, Switzerland
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Univercell-Biosolutions, Toulouse, France
Associated partners
  • Jdrf International, New York, United States
  • The Leona M. and Harry B. Helmsley Charitable Trust , New York, United States


Project coordinator
Chantal Mathieu
Katholieke Universiteit Leuven
Project contact e-mail